Merck’s earnings call mixed immediate pressure—from vaccine volatility, RSV softness, and acquisition accounting—with evidence that oncology leadership, targeted dealmaking, and a rich pipeline can ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results